Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy (CAR-T) used for multiple relapsed/refractory B-cell lymphoma indications, including large B-cell lymphoma, follicular lymphoma, and primary central nervous system lymphoma in adults. FDA product records show approvals and updates through February 2026.
New market reports forecast significant expansion in CAR T-cell therapy, US pharmaceutical drug delivery, and healthcare nanotechnology sectors, driven by chronic disease prevalence and technological advances.
Citius Pharmaceuticals reported $3.9 million in first revenue from LYMPHIR's December 2025 launch for cutaneous T-cell lymphoma, while subsidiary Citius Oncology announced positive Phase 1 data showing 86% response rate when LYMPHIR was administered prior to CAR-T therapy in high-risk lymphoma patients.
The CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%. The Cell & Gene Therapy Drug Delivery Devices Market is forecast to climb to USD 26.79 billion by 2032 from USD 3.39 billion in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04071366 |
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy |
COMPLETED | PHASE2 |
| NCT03642626 |
MT2017-45: CAR-T Cell Therapy for Heme Malignancies |
ACTIVE_NOT_RECRUITING | PHASE2 |
